Ensoma, founded in 2019, is a biotechnology company with the goal of expanding the reach of the curative power of genomic medicine by seeking to pioneer a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies aim to be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma is headquartered in Boston, Massachusetts.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/13/2023 | Series B | $92.5MM | $xx.xx | $222.4MM | ||
Price per Share
$xx.xx
Shares Outstanding
68,773,582
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
|
||||||
02/11/2021 | Series A-1 | $10.55MM | $xx.xx | $138.01MM | ||
Price per Share
$xx.xx
Shares Outstanding
13,563,792
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
|
||||||
02/11/2021 | Series A | $60MM | $xx.xx | $138.01MM | ||
Price per Share
$xx.xx
Shares Outstanding
35,688,784
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
|